MedPath

ZELAPAR

These highlights do not include all the information needed to use ZELAPAR safely and effectively. See full prescribing information for ZELAPAR.ZELAPAR (selegiline hydrochloride) orally disintegrating tabletsInitial U.S. Approval: 2006

Approved
Approval ID

380d7717-2a79-42f3-a712-efe5e7696ba0

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 1, 2021

Manufacturers
FDA

Bausch Health US, LLC

DUNS: 831922468

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

SELEGILINE HYDROCHLORIDE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0187-0453
Application NumberNDA021479
Product Classification
M
Marketing Category
C73594
G
Generic Name
SELEGILINE HYDROCHLORIDE
Product Specifications
Route of AdministrationORAL
Effective DateJune 1, 2021
FDA Product Classification

INGREDIENTS (7)

SELEGILINE HYDROCHLORIDEActive
Quantity: 1.25 mg in 1 1
Code: 6W731X367Q
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
ASPARTAMEInactive
Code: Z0H242BBR1
Classification: IACT
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT
FERRIC OXIDE YELLOWInactive
Code: EX438O2MRT
Classification: IACT
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327L
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ZELAPAR - FDA Drug Approval Details